Healthequity Insider Sold Shares Worth $2,417,900, According to a Recent SEC Filing-February 2024-www.financetom.com

Healthequity Insider Sold Shares Worth $2,417,900, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Healthequity Insider Sold Shares Worth $2,417,900, According to a Recent SEC Filing

Dec 13, 2024 2:24 PM

05:05 PM EST, 12/13/2024 (MT Newswires) -- Stuart B. Parker, Director, on December 12, 2024, sold 25,000 shares in Healthequity ( HQY ) for $2,417,900. Following the Form 4 filing with the SEC, Parker has control over a total of 19,061 shares of the company, with 19,061 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1428336/000141588924029330/xslF345X05/form4-12132024_091227.xml

Previous page： China tells Morgan Stanley it welcomes more US financial institutions, Xinhua reports Next page： Quantum BioPharma Receives Australian Ethics Committee Approval for Phase 2 FSD202 Trial

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

China tells Morgan Stanley it welcomes more US financial institutions, Xinhua reports

May 28, 2025

BEIJING, May 28 (Reuters) - China's Vice Premier He Lifeng told Morgan Stanley Co-President Daniel Simkowitz that Beijing welcomes more U.S. financial institutions and long-term capital to deepen cooperation, the official Xinhua news agency reported. He said at a meeting in Beijing that U.S. financial institutions, including Morgan Stanley ( MS ), are welcomed to actively participate in the development...

Quantum BioPharma Receives Australian Ethics Committee Approval for Phase 2 FSD202 Trial

May 28, 2025

08:49 AM EDT, 05/28/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) on Wednesday said it has received approval by the human ethics review committee (HREC) in Australia for its Phase 2 trial assessing its compound FSD202 for treating nociplastic pain associated with idiopathic mast cell activation syndrome. The trial will run for 56 days and enroll 60 patients with...

iTeos Therapeutics to Wind Down Operations

May 28, 2025

08:49 AM EDT, 05/28/2025 (MT Newswires) -- iTeos Therapeutics ( ITOS ) said Wednesday it intends to wind down operations after a strategic review of its development pipeline, business prospects, and financial position. iTeos plans to focus on leveraging its cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of its intellectual property and...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...